COVID-19 CVD Registry

To better understand the COVID-19 pandemic, the American Heart Association has developed a new registry for hospitals and health systems caring for COVID-19 patients.  

AUDIOCAST SERIES - Quality Improvement in the Time of COVID-19 NOW AVAILABLE

Listen to Dr. Sandeep Das and other experts across the country as they discuss topics related to Quality Improvement in the time of COVID-19. 

New Episodes!

As physicians, scientists and researchers worldwide struggle to understand the novel coronavirus (COVID-19) pandemic, the American Heart Association (AHA) is developing a novel registry to aggregate data and aid research on the disease, treatment protocols and risk factors tied to adverse cardiovascular outcomes.

”Having sufficient data is the first step to understanding the impact of COVID-19 on cardiovascular health,“ said John Warner, M.D., FAHA, chair of the quality oversight committee and past volunteer president of the American Heart Association and executive vice president for Health System Affairs at the University of Texas Southwestern Health System in Dallas, Texas. “As a trusted resource for data and research, with an entry point in more than 2,400 U.S. hospitals, the American Heart Association is uniquely positioned to gather data quickly and accurately.”

"Having sufficient data is the first step to understanding the impact of COVID-19 on cardiovascular health"

-John Warner, M.D., FAHA

Several studies have reported COVID-19 patients presenting with or developing heart failure, cardiogenic shock, stroke and lethal arrhythmias secondary to the disease. However, these studies have consistently been limited by the lack of a structured collection of data raising concerns about indication bias for most laboratory testing. Further, several of these studies are single-center descriptive assessments, limiting their generalizability.

The AHA has created a quality improvement registry to better understand the clinical treatment patterns and variations, including the collection of biomarkers, and cardiovascular outcomes in hospitalized COVID-19 patients across the nation. The registry will focus on real-time  data from acute care hospitals to better help clinicians and researchers understand and provide feedback to healthcare organizations on how to best treat COVID-19 patients.

The AHA’s COVID-19 CVD Registry powered by Get With The Guidelines® (GWTG) builds on 20 years of successful hospital quality improvement efforts. The no-cost registry will help inform the larger medical community and the aggregated, deidentified data set will be available to researchers through the Association’s Institute for Precision Cardiovascular Medicine in coming months.

Fighting COVID-19 Through Data

During the COVID pandemic, fellows were put on leave, procedures were cancelled, and many clinicians found themselves more idle and itching to contribute. Tracy Wang, MD, MHS, MS, FAHA shares how these doctors are continuing to impact COVID treatments. 

Thank You to Our Participating Hospitals!

The American Heart Association recognizes and thanks these hospitals for leading the way toward better health. 

Participating Hospitals

Medical Data Image showing graphs

Data Collection

Data collection and feedback reporting are performed using the American Heart Association's IQVIA Registry Platform, an online interactive system provided by IQVIA. Enhancements have been made since the release of the COVID-19 CVD Registry to allow for bulk upload of data to reduce abstraction burden. 

Benefits of Participation

In addition to being specifically designed to track all hospitalized COVID-19 patients to get real-time feedback from across the nation, the registry will include the following features:

  • Access to national and regional benchmarks
  • Ability to use key learnings and data for future pandemic preparedness
  • Leverage the registry for powerful rapid research
  • Future iterations will include enhanced measures and reports

Exterior image of a hospital
Image of Medical Doctors

How to Enroll

In response, the AHA is creating the multicenter registry to collect biomarkers, clinical data and cardiovascular outcomes in COVID-19 patients. The registry will focus on granular data collection from centers that routinely test biomarkers in COVID-19 patients.

To participate in the registry, complete the information request form and our COVID-19 CVD Registry Team members will be in touch. For questions, please contact

Additional resources and guidance for health care professionals on COVID-19 can be found here.

The American Heart Association's COVID-19 CVD Registry powered by Get With The Guidelines® is currently being offered AT NO COST to hospitals and health systems

Support from the American Heart Association


The COVID-19 CVD Registry is supported by the American Heart Association and our Quality and Systems Improvement staff. These experts have been your partners in improving care, understanding the registry elements and are available to answer any questions you may have on how to operationalize the registry at your facility.